Alternatively, XU et al. explored MIR17HG as a pivotal BLNK inhibitor, revealing that BLNK suppression enhances metastatic potential and tumorigenesis in CRC [15]. The gene discussed is MIR17HG; the disease is colorectal carcinoma.